本帖最后由 老马 于 2012-1-13 21:20 编辑
4 p# a ~. [* f) [/ h% ?
. l6 F x* O2 z- }2 e% z爱必妥和阿瓦斯丁的比较" ?& m) B, j8 W' @2 ~# L
# `8 p# n1 {6 k
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/4 D. p7 M2 g) R7 A
% Y6 R: |! `6 f2 U) A( C+ u2 ?
R, \2 Y& H" X. J [# {, a/ j
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* t2 T7 L/ O7 ^8 ^
==================================================9 C, J. Z" _; O D0 G1 y7 ?
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)2 l/ A: x; |6 ]
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.4 ~3 L0 }0 |2 |0 _6 ?& ]/ K
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
. O2 z. O( E) w
|